The Roles of Tissue Factor in Malignant Gliomas

Completed

Conditions studied: Venous Thromboembolism, Brain Tumors

In brief

To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma

Key facts

Study ID

NCT00201903

Run by

Ontario Clinical Oncology Group (OCOG)

People needed

30

Starts

2004-01-01

Expected to finish

2006-10-01

Last updated by the study team

2017-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• participation in PRODIGE
• adult patients
• newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
• undergone craniotomy or stereotactic biopsy > 2 days and < 4 weeks before

You may not qualify if…

• have known hereditary thrombophilia
• are receiving experimental antiangiogenic therapy

Where it is running

• Henry Ford Hospital — Detroit, Michigan, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Cross Cancer Institute — Edmonton, Alberta, Canada
• CancerCare Manitoba — Winnipeg, Manitoba, Canada
• Toronto-Sunnybrook Regional Cancer Centre — Toronto, Ontario, Canada
• Princess Margaret Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.